Here are the 10-Q quarterly reports from Shorepower Technologies (SPEV) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SPEV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SPEV filings page.
Aeternum Health, Inc. (formerly Shorepower Technologies) reports a sharp downturn in operations and prepares a major business pivot. Q1 2026 revenue fell to $2,260 from $164,657 a year earlier, producing a negative gross margin of $11,977 and a net loss of $139,655 after prior-year net income.
At March 31, 2026, the company held cash of $19,156, had a working capital deficit of $1,158,363, total liabilities of $2,137,041, and an accumulated deficit of $3,417,796, leading management to disclose substantial doubt about its ability to continue as a going concern. Operations are being funded through related-party loans and small equity raises.
The company has signed a merger agreement with Aeternum Health LLC under which it will divest its transportation electrification business and refocus on longevity and anti‑aging healthcare. Aeternum will contribute at least $1.5 million in cash plus intellectual property, while Paul Mann will receive 51% of the common equity and 2,000,000 Series B preferred shares with super‑voting rights. Existing CEO Jeff Kim has agreed to cancel up to 13,000,000 common shares, and authorized common stock has been increased from 100,000,000 to 250,000,000 to support the transaction.
Shorepower Technologies (SPEV) filed its Q3 2025 10‑Q, showing nine‑month revenue of $180,124, up 241% from $52,779 a year ago, mainly from new government contracts. Gross margin for the period was $111,093, and the net loss narrowed to $237,824 from $311,005. For Q3 alone, revenue was $8,345 and the net loss was $137,860.
Liquidity remains tight: cash was $53,881 as of September 30, 2025, with negative working capital of $980,937 and a stockholders’ deficit of $1,899,616. The company disclosed “substantial doubt” about its ability to continue as a going concern. Related‑party notes and accrued interest totaled significant balances, and disclosure controls were deemed not effective as of September 30, 2025. All 11,000,000 outstanding warrants expired during 2025. As of November 10, 2025, 49,190,204 common shares were outstanding.